希罗达联合奥沙利铂治疗晚期胃癌的临床疗效观察

Clinical study of Xeloda(capecitabine) plus oxaliplatin(L-OHP) in treatment of advanced gastric carcinoma

目的:观察希罗达(Xeloda)联合奥沙利铂(L-OHP)治疗晚期胃癌的疗效和毒副作用。方法:L-OHP130mg/m2,加入5GS500ml中静脉滴注2小时,第一天,Xeloda1000mg/m2,2次/d口服,第1-14天,21天为一周期,连用2个周期后评价疗效。结果:23例患者中,CR1例PR11例SD8例PD3例,RR52.2,中位疾病进展时间(TTP)5.8个月(3-8个月),中位生存期(MST)11个月(6-17个月),1年生存率34.8。毒副反应主要为骨髓抑制、消化道反应、神经毒性和手足综合征,大多能耐受。结论:希罗达联合奥沙利铂治疗晚期胃癌具有较好的疗效,毒副作用小,能显著提高患者的生活质量,值得临床推广。

Objective：To evaluate the efficacy and toxicity of Xeloda（capecitabine） plus Oxaliplation （L- OHP） in the treatment of advanced gastric carcinoma. Methods： L -OHP was administered at a dose of 130mg/m2 with 500ml of 5%GS by drip infusion for 2 hours on day 1 ,Xeloda !000mg/m2 twice daily was adopted orally on day 1 - 14. The chemotherapy was repeated every 21 days and the efficacy was evaluated after 2 cycles. Results： Twenty - one patients were evaluable for treament outcome. One obtained CR, 11 PR,8 SD,3 PD, and the overall response rate was 52.2% ,TIP was 5.8 months（3 - 8months） ,MST was 11 months （6 - 17months） and one - year survival rate was 34.8 %. The major toxicity and side effets were myelosuppression and gastrointestinal, neural toxicity and hand - foot syndrome, but they were acceptable. Conclusion： Xeloda plus L - OHP is a effective regimen for patient with ad- vanced gastric carcinoma,less side effects.